アトピー性皮膚炎の世界市場：2024年～2031年

概要

アトピー性皮膚炎の世界市場は、2023年に94億4,000万米ドルに達し、2031年には259億8,000万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは13.7%で成長する見込みです。

アトピー性皮膚炎、一般に湿疹と呼ばれるものは、かゆみ、赤み、腫れを特徴とする慢性炎症性皮膚疾患です。湿疹は、アレルギー性鼻炎（花粉症）や喘息も含む「アトピー三徴」と呼ばれる疾患群の一部です。アトピー性皮膚炎は小児期に発症することが多く、成人期まで続くこともありますが、重症度や症状は時間の経過とともに変化します。慢性のアトピー性皮膚炎は、乾皮症（皮膚が乾燥し、鱗状になる）、皮膚のひび割れ、さらには開放性のただれにつながることがあります。フレア（再燃）」時には、症状が著しく悪化する一方で、症状が治まったり寛解したりすることもあります。

アトピー性皮膚炎治療に対する需要は、特に小児における疾患の有病率の増加と、より効果的な治療法の必要性により、大きく伸びています。例えば、アトピー性皮膚炎Atlas Organizationによると、アトピー性皮膚炎の有病率は高く、小児の最大20％、成人の最大10％が罹患しています。その疾病負担は、障害調整生存年数で測定して、非致死的疾患では世界第15位、皮膚疾患では世界第1位となっています。したがって、2022年には、アトピー性皮膚炎は複雑な病因を持つ一般的で負担の大きい皮膚疾患と考えられます。また、従来の局所治療では不十分な場合が多い、中等度から重度の症例の増加も市場の需要に拍車をかけています。

市場力学：

促進要因と阻害要因

アトピー性皮膚炎の有病率の上昇

アトピー性皮膚炎は、主に個人の皮膚に影響を及ぼす慢性疾患です。この疾患は通常、0～4歳の幼児に発症します。アトピー性皮膚炎の有病率と発症率は常に上昇しており、近年世界の負担となっています。例えば、2022年に発表されたアトピー性皮膚炎に関する最新の世界報告書によると、全世界で約2億2,300万人がアトピー性皮膚炎に苦しんでおり、このうち小児（1～4歳）が4,300万人を占めています。

全米湿疹協会によると、米国では約960万人の子供（18歳以下）がアトピー性皮膚炎に罹患しており、人口の約3分の1が中等症から重症です。また、成人（18歳以上）では1,650万人近くが罹患しており、人口の約40％が中等度から重度の罹患者です。

さらに、いくつかの疫学調査では、近い将来、アトピー性皮膚炎の罹患率が増加傾向にあることが報告されています。ヘルスケア産業の拡大に伴い、症例数の増加と相まって診断・治療率は上昇すると予想され、予測期間において市場はプラスに推進されます。

例えば、Frontiers in Microbiology Journalに掲載された中国の人口を対象とした疫学調査によると、有病率は10～19歳の年齢層で着実に増加しています。人口の増加に伴い、この増加傾向は将来的に膨大な症例数を生み出す可能性があります。

患者のアドヒアランスとコンプライアンス

患者のアドヒアランスとコンプライアンスは、アトピー性皮膚炎市場における重要な懸念事項です。慢性的で再発しやすい疾患であるため、症状管理のために長期にわたる一貫した治療が必要となることが多いからです。しかし、特に現在の治療レジメンは時間がかかり、時には不快なものであるため、アドヒアランスが悪いことが一般的です。

多くの患者、特に中等度から重度のアトピー性皮膚炎の患者は、毎日何度も塗布する必要のある外用治療薬を処方されています。これは、特に治療が皮膚を刺激したり、脂っぽく感じたりする場合には、面倒であり、一貫して維持することが難しいです。例えば、米国国立衛生研究所（NIH）によると、皮膚科疾患では、治療の不服従が問題であり、治療成績に悪影響を及ぼします。慢性皮膚病と診断された患者の約50％は、皮膚科医から処方された治療を守っていなかった。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • アトピー性皮膚炎の普及率の上昇
    • 製品開発活動と規制承認の増加
  • 抑制要因
    • 患者の遵守とコンプライアンスに関する懸念
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• パイプライン分析
• 疫学分析
• アンメットニーズ

第6章 治療の種類別

• コルチコステロイド
  • ヒドロコルチゾン
  • モメタゾン
  • ベタメタゾン
  • プレドニゾン
  • その他
• 免疫抑制剤
  • カルシニューリン阻害剤
    • シクロスポリン
    • タクロリムス
    • ピメクロリムス
    • その他
  • JAK阻害剤
    • アブロシチニブ
    • ウパダシチニブ
    • その他
  • PDE-4阻害剤
  • その他
• 生物学的製剤
  • デュピルマブ
  • トラロキヌマブ
  • その他
• 抗ヒスタミン薬
• その他

第7章 患者タイプ別

• 子供
• 大人

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Regeneron Pharmaceuticals Inc
• Sanofi S.A
• AbbVie Inc
• Eli Lilly and Company
• Galderma Inc
• LEO Pharma Inc.
• Incyte Corporation
• Arcutis Biotherapeutics, Inc
• Otsuka Pharmaceutical Co., Ltd

第12章 付録

Overview

The global atopic dermatitis market reached US$ 9.44 billion in 2023 and is expected to reach US$ 25.98 billion by 2031, growing at a CAGR of 13.7% during the forecast period 2024-2031.

Atopic dermatitis, commonly referred to as eczema is a chronic inflammatory skin condition characterized by itchy, red and swollen skin. It's part of a group of conditions known as the "atopic triad," which also includes allergic rhinitis (hay fever) and asthma. Atopic dermatitis often starts in childhood and may continue into adulthood, though the severity and symptoms can fluctuate over time. Chronic atopic dermatitis can lead to xerosis (dry, scaly skin), skin cracking and even open sores. During "flares," symptoms worsen significantly, while at other times, symptoms may subside or enter remission.

The demand for atopic dermatitis treatments is growing significantly, driven by increasing disease prevalence, especially among children and the need for more effective therapies. For instance, according to the Atopic Dermatitis Atlas Organization, the prevalence of atopic dermatitis is high, affecting up to 20% of children and up to 10% of adults. The burden of disease ranks 15th worldwide for non-fatal diseases and number one for skin diseases, measured in disability-adjusted life years. Therefore, in 2022, atopic dermatitis is considered a common and burdensome skin disease with a complex pathogenesis. The market demand is also fueled by the rise in moderate-to-severe cases, where traditional topical treatments are often insufficient.

Market Dynamics: Drivers & Restraints

Rising prevalence of atopic dermatitis

Atopic dermatitis is a chronic condition that mainly affects the skin of an individual. The condition is usually diagnosed in younger children between 0 to 4 years. The prevalence and incidence of atopic dermatitis is constantly rising and has become a global burden in recent years. For instance, according to the latest global report on Atopic Dermatitis published in 2022, approximately 223 million population across the globe suffer from atopic dermatitis and among these children (1-4 years of age) accounted for 43 million.

According to the National Eczema Association, nearly 9.6 million children (below 18 years of age) in the United States have atopic dermatitis, and approximately one-third of the population has moderate to severe disease. Moreover, nearly 16.5 million adults (above 18 years of age) are diagnosed with the condition, and approximately 40% of the population has moderate to severe disease.

Moreover, several epidemiology studies have reported an increasing trend in the incidence of atopic dermatitis in the near future. With the expanding healthcare industry, the diagnosis and treatment rate is anticipated to increase combined with the rising number of cases propelling the market positively in the forecast period.

For instance, an epidemiology study published in Frontiers in Microbiology Journal among the Chinese population has stated that the prevalence is steadily growing among the 10-19 age group population. With the growing population, this increasing trend may create a huge burden of cases in the future.

Patient adherence and compliance concerns

Patient adherence and compliance are critical concerns in the atopic dermatitis market, as the chronic, relapsing nature of the disease often requires long-term, consistent treatment for symptom management. However, poor adherence is common, particularly due to the time-intensive and sometimes uncomfortable nature of current treatment regimens.

Many patients, especially those with moderate-to-severe atopic dermatitis, are prescribed topical treatments that need multiple daily applications. This can be cumbersome and challenging to maintain consistently, especially if the treatment irritates or feels greasy on the skin. For instance, according to the National Institute of Health (NIH), in dermatological diseases, non-adherence to treatment is problematic and related to negative therapeutic outcomes. About 50% of patients diagnosed with chronic skin diseases were not adherent to the treatments prescribed by their dermatologists.

Segment Analysis

The global atopic dermatitis market is segmented based on treatment type, patient type, distribution channel and region.

Treatment Type:

The corticosteroids segment is expected to dominate the global atopic dermatitis market share

The corticosteroids segment holds a major portion of the atopic dermatitis market share and is expected to continue to hold a significant portion of the market share over the forecast period. Corticosteroids are essential medications for the treatment of atopic dermatitis (AD) and especially so when it comes to the management of flare-ups and inflammation. As anti-inflammatory agents, these drugs markedly alleviate the signs of cutaneous reddening, papules and pus-filled blisters, pruritis and discomfort caused by the AD condition.

Corticosteroids come in a number of formulations: topical creams, ointments, lacquers which come in various 'strengths', from low to super potent depending on the weight of the condition. For mild- to moderate-severity cases, low to medium-potency corticosteroid agents are commonly prescribed but for severe exacerbations, higher potency options are given or those thick dense skin areas such as palms and soles.

The administration of these medications decreases the reactivity of certain parts of the immune system and inflammation of the skin, and allows a patient to recover from chronic and acute forms of the disease. For instance, in July of 2024, ZORYVE (roflumilast) cream 0.15% was commercially launched in the United States to treat mild to moderate atopic dermatitis in adults and children aged 6 and upby Arcutis Biotherapeutics, Inc. which is a commercial-stage biotechnology firm dedicated to the development of significant innovations in the field of immuno-dermatology.

ZORYVE is a cream that can be applied once daily to treat afflicted skin without the need for steroids. It acts fast to reduce itching and resolve impacted skin while also helping to control the condition over the long term.

Moreover, some of the factors that need to be considered when selecting a topical corticosteroid include the age of the patient, the area being treated, and rate of absorption. In general, infants may need a less potent preparation for the management of atopic dermatitis flares. In contrast, teenagers may use a medium or a high-level potency drug. Peripheral absorption of these corticosteroids is maximum in thin areas such as the face and perineum and minimal in thicker regions like the palms and soles. Such cases may require mid-potency or high-potency topical drugs for effective management.

The immunosuppressants segment is the fastest-growing segment in the atopic dermatitis market

The immunosuppressants segment is expected to be the fastest-growing segment over the forecast period. Immunosuppressants are emerging as one of the fastest-growing segments in the atopic dermatitis market due to their effectiveness in managing moderate-to-severe cases that do not respond well to traditional treatments. This growth is driven by the need for therapies that target the underlying immune dysfunction in atopic dermatitis, providing more substantial and longer-lasting relief from symptoms.

Immunosuppressants, including JAK inhibitors such as upadacitinib (Rinvoq) and abrocitinib (Cibinqo) are designed to inhibit specific immune pathways associated with atopic dermatitis inflammatory processes. By directly modulating these pathways, these therapies can reduce inflammation, itching and skin lesions more effectively than non-targeted treatments, improving patient outcomes significantly.

North America is expected to hold a significant position in the global atopic dermatitis market

North America region is expected to hold the largest market share over the forecast period. The healthcare system in North America, especially in the USA, is robust with equipped hospitals, research organizations, and dermatology clinics. This system also aids in diagnosis, treatment and management of Atopic Dermatitis thus influencing the growth of the market. The healthcare services offered are of good quality because there are professionals such as dermatologists and allergists available.

The region leads other regions of the world in the adoption and implementation of modern technologies in the health sector. Most of its countries, particularly the United States where attention to R&D is very high, have been able to come up with new therapies and diagnostic technologies for atopic dermatitis.

For instance, in September 2024, Eli Lilly revealed that Ebglyss an IL-13 targeting inhibitor, has been accepted by USFDA for the treatment of moderate to severe atopic dermatitis (AD). The drug has been approved for use by Adults as well as teens with a 12-year-old or older with a minimum body weight of 40kg who have inadequate AD disease control despite the use of topical prescription therapies.

Moreover, in August 2023, to further enhance the effectiveness of ARCTIVA products, the latter also contains the unique patented HYDROSURF technology invented by the company along with active ingredients approved by the FDA. Research and tests show that the fermented components in HYDROSURF reduce the surface tension of different liquids, making them appropriate for use in formulations meant to treat dry skin disorders like dermatitis, eczema, and even flare-ups of psoriasis. Salicylic acid and colloidal oatmeal are used in each of these psoriasis and eczema therapies to address the main symptoms of their respective conditions.

Asia Pacific is growing at the fastest pace in the atopic dermatitis market

The Asia Pacific region is experiencing the fastest growth in the atopic dermatitis market driven by a combination of rising prevalence, increased healthcare spending, improved access to advanced therapies and greater awareness of dermatological health. For instance, according to Sanofi. Anil Raina, General Manager, Sanofi, declared that more public awareness is required for innovative treatments for difficult-to-treat illnesses like atopic dermatitis to know more about the advancements in the management of atopic dermatitis in India which impacts more than 28 million lives.

Competitive Landscape

The major global players in the atopic dermatitis market include Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi S.A, AbbVie Inc, Eli Lilly and Company, Galderma Inc, LEO Pharma Inc., Incyte Corporation, Arcutis Biotherapeutics, Inc, Otsuka Pharmaceutical Co., Ltd and among others.

Emerging Players

The emerging players in the atopic dermatitis market include Almirall, S.A, Aclaris Therapeutics Inc, Kiniksa Pharmaceuticals, Cara Therapeutics, VYNE Therapeutic and among others.

FDA Approvals

• In September 2024, Eli Lilly and Company cleared that the U.S. Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies. EBGLYSS works by targeting eczema inflammation throughout the body that can lead to dry, itchy and irritated skin.
• In April 2024, Dermavant Sciences released that the U.S. Food and Drug Administration (FDA) accepted the company's Supplemental New Drug Application (sNDA) for VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older. The Prescription Drug User Fee Act ("PDUFA") action date assigned by the Agency is in Q4 2024.
• In July 2024, Arcutis Biotherapeutics, Inc. cleared that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ZORYVE is a once-daily, steroid-free cream that provides rapid disease clearance and significant reduction in itch and has been specifically developed to be a treatment option for long-term disease control.

Why Purchase the Report?

• To visualize the global atopic dermatitis market segmentation based on treatment type, patient type, distribution channel and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the atopic dermatitis market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global atopic dermatitis market report would provide approximately 62 tables, 53 figures and 197 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Patient Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Atopic Dermatitis
    • 4.1.1.2. Rising Product Development Activities and Regulatory Approvals
  • 4.1.2. Restraints
    • 4.1.2.1. Patient Adherence and Compliance Concerns
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Pipeline Analysis
• 5.8. Epidemiology Analysis
• 5.9. Unmet Needs

6. By Treatment Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 6.1.2. Market Attractiveness Index, By Treatment Type
• 6.2. Corticosteroids*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Hydrocortisone
  • 6.2.4. Mometasone
  • 6.2.5. Betamethasone
  • 6.2.6. Prednisone
  • 6.2.7. Others
• 6.3. Immunosuppressants
  • 6.3.1. Calcineurin Inhibitors
    • 6.3.1.1. Cyclosporine
    • 6.3.1.2. Tacrolimus
    • 6.3.1.3. Pimecrolimus
    • 6.3.1.4. Others
  • 6.3.2. JAK Inhibitors
    • 6.3.2.1. Abrocitinib
    • 6.3.2.2. Upadacitinib
    • 6.3.2.3. Others
  • 6.3.3. PDE-4 Inhibitors
  • 6.3.4. Others
• 6.4. Biologics
  • 6.4.1. Dupilumab
  • 6.4.2. Tralokinumab
  • 6.4.3. Others
• 6.5. Antihistamines
• 6.6. Others

7. By Patient Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 7.1.2. Market Attractiveness Index, By Patient Type
• 7.2. Children*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Adults

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Pfizer Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Regeneron Pharmaceuticals Inc
• 11.3. Sanofi S.A
• 11.4. AbbVie Inc
• 11.5. Eli Lilly and Company
• 11.6. Galderma Inc
• 11.7. LEO Pharma Inc.
• 11.8. Incyte Corporation
• 11.9. Arcutis Biotherapeutics, Inc
• 11.10. Otsuka Pharmaceutical Co., Ltd

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us